Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydroxyamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.36 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.33 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 0.32 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL7460403 | 0.96 | ACHE (0.34) | ACHEALDH1A1CYP2C9HPGDHSD17B10 | |
| Hydroxyamine SCHEMBL27593366 | 0.96 | — | — | |
| Methylamine SCHEMBL6886090 | 0.87 | ALDH1A1 (0.35) | ACHEALDH1A1CYP2C9HPGDHSD17B10 | |
| Methyl Alcohol SCHEMBL4500223 | 0.87 | ALDH1A1 (0.35) | ACHEALDH1A1CYP2C9HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL10651080 | 0.87 | ALDH1A1 (0.36) | ALDH1A1CYP2C9HPGDHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL8812637 | 0.87 | ALDH1A1 (0.36) | ALDH1A1CYP2C9HPGDHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL844 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL7930062 | 0.87 | ALDH1A1 (0.36) | ALDH1A1CYP2C9HPGDHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL5325738 | 0.87 | ALDH1A1 (0.36) | ALDH1A1CYP2C9HPGDHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL5047658 | 0.87 | ALDH1A1 (0.36) | ALDH1A1CYP2C9HPGDHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46424-E1 | Method for producing 3-amidinophenylalanine derivatives | WILEX AG (DE) | 2017-06-06 | — | — | US | disclosed |
| US-8642761-B2 | Method for producing 3-amidinophenylalanine derivatives | WILEX AG (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20120065398-A1 | METHOD FOR PRODUCING 3-AMIDINOPHENYLALANINE DERIVATIVES | WILEX AG (DE) | 2012-03-15 | — | — | US | disclosed |
| US-8088921-B2 | Method for producing 3-amidinophenylalanine derivatives | WILEX AG (DE) | 2012-01-03 | — | — | US | disclosed |
| US-20110087025-A1 | METHOD FOR PRODUCING 3-AMIDINOPHENYLALANINE DERIVATIVES | WILEX AG (DE) | 2011-04-14 | — | — | US | disclosed |
| US-7884206-B2 | N-alpha-2,4,6-triisopropylphenylsulfonyl-3-cyano-(L)-phenylalanine-4-ethoxycarbonyl piperazide dissolved in ethanol, mixed with hydroxylamine hydrochloride to produce N- alpha -2,4,6-Triisopropylphenylsulfonyl-3-amidino-(L)-phenylalanine-4-ethoxycarbonyl piperazide hydrochloride, reduction with H2, Pd/C | WILEX AG (DE) | 2011-02-08 | — | — | US | disclosed |
| US-20070123706-A1 | Method for producing 3-amidinophenylalanine derivatives | WILEX AG | 2007-05-31 | — | — | US | disclosed |
| US-7211670-B2 | Method for producing 3-amidinophenylalanine derivatives | WILEX AG (DE) | 2007-05-01 | — | — | US | disclosed |
| US-20050176962-A1 | Method for producing 3-amidinophenylalanine derivatives | WILEX AG (DE) | 2005-08-11 | — | — | US | disclosed |
| EP-0796245-B1 | PROCESS FOR THE PREPARATION OF AMIDINO PHENYL PYRROLIDINE BETA-ALANINE UREA ANALOGS | SEARLE & CO (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0796245-A1 | PROCESS FOR THE PREPARATION OF AMIDINO PHENYL PYRROLIDINE $g(b)-ALANINE UREA ANALOGS | G.D. SEARLE & CO. (US) | 1997-09-24 | — | — | EP | disclosed |
| US-5659063-A | AMINE-BLOCKED METHIONINE ANALOG CYCLIZABLE TO A LACTAM IN NONVOLATILE OR NONTOXIC REAGENTS; ANTITHROMBOTIC AGENTS | G. D. SEARLE & CO. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5610296-A | CHEMICAL INTERMEDIATES OF ANTITHROMBOTICS | G. D. SEARLE & CO. (US) | 1997-03-11 | — | — | US | disclosed |
| US-5576447-A | Process for the preparation of amidino phenyl pyrrolidine β-alanine urea analogs | G. D. SEARLE & CO. (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1996017827-A1 | PROCESS FOR THE PREPARATION OF AMIDINO PHENYL PYRROLIDINE β-ALANINE UREA ANALOGS | G.D. SEARLE & CO. (US) | 1996-06-13 | — | — | WO | disclosed |
| US-5484946-A | CYCLIZATION AND DEHYDRATION A METHIONINE DERIVATIVE | G. D. SEARLE & CO. (US) | 1996-01-16 | — | — | US | disclosed |
| CN-1106388-A | 1,2-dihydro-2-oxo-pyridine | MERCK PATENT GMBH (DE) | 1995-08-09 | — | — | CN | disclosed |
| US-4684642-A | BACTERICIDES | PFIZER INC. (US) | 1987-08-04 | — | — | US | disclosed |
| US-4684641-A | BACTERICIDES | PFIZER INC. (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0168177-A2 | Cephalosporin antibiotics | Pfizer Limited (GB) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123706-A1 | Method for producing 3-amidinophenylalanine derivatives | APEH, PAH, DAO | ACHE 2545/4885CACNA1B 4137/4885PRKCI 1801/4885 |
| US-20110087025-A1 | METHOD FOR PRODUCING 3-AMIDINOPHENYLALANINE DERIVATIVES | PAH, APEH, DAO | ACHE 2732/4885CACNA1B 3968/4885PRKCI 1897/4885 |
| US-20050176962-A1 | Method for producing 3-amidinophenylalanine derivatives | APEH, ANPEP, PAH | ACHE 2522/4885CACNA1B 4357/4885PRKCI 3086/4885 |
| US-20120065398-A1 | METHOD FOR PRODUCING 3-AMIDINOPHENYLALANINE DERIVATIVES | PAH, APEH, DAO | ACHE 2732/4885CACNA1B 3968/4885PRKCI 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.